RSLS — Trading Suspension of ReShape Lifesciences Inc. Common Stock
Jun 6, 2025, 12:00:00 AM UTC
Summary
ReShape Lifesciences Inc. will face a trading suspension of its common stock on June 6, 2025, after failing to meet Nasdaq's minimum stockholders' equity requirement of $2.5 million. Nasdaq had previously granted the company an extension until May 27, 2025, to comply, but determined it did not meet the conditions of compliance. The company has the option to appeal this decision by June 4, 2025, which would prevent the suspension from taking effect while the appeal is reviewed. No assurance can be given that the appeal will be successful or that future compliance with Nasdaq Listing Rules will be achieved.
Company
RESHAPE LIFESCIENCES INC (RSLS)NASDAQ — Healthcare: Manufacturing, Medical Devices: Surgical & Medical Instruments & Apparatus
www.reshapelifesciences.comSimilar Events
Common Stock Suspension from Nasdaq Trading
LogicMark, Inc.'s common stock will be suspended from trading on Nasdaq effective June 2, 2025, due to failure to meet the minimum bid price requirement of $1.00 per share, as mandated by Nasdaq Listing Rule 5550(a)(2). The company has opted not to appeal the delisting decision following a notification received from Nasdaq's Hearings Panel on May 29, 2025. Post-suspension, LogicMark's common stock is expected to be quoted on the OTC Markets under the symbol "LGMK." This strategic shift reflects the company's ongoing efforts to remain accessible to investors despite the Nasdaq delisting.
Delisting NotificationPotential Suspension of Trading on Nasdaq
The InterGroup Corporation has been notified by Nasdaq that its securities will be suspended from trading as of June 5, 2025, if it fails to file an appeal. This action follows the company's non-compliance with Nasdaq's minimum market value requirement of $35 million, a status unrectified since May 20, 2025. The company intends to file an appeal by June 3, 2025, which, if filed, would delay the suspension pending a decision by a hearing panel.
Trading SuspensionTrading in Ordinary Shares and Warrants Suspension
Silexion Therapeutics Corp announced a suspension of trading in its ordinary shares and warrants, effective June 2, 2025. This decision follows the release of an updated corporate presentation and press release detailing an expanded development plan for SIL204, a next-generation siRNA candidate targeting KRAS-driven pancreatic cancer. The revised strategy incorporates both systemic and intratumoral administration, aiming to enhance treatment efficacy against aggressive cancers. The company plans to conduct further studies throughout 2025, with potential regulatory submissions anticipated for later in the year and into 2026. Trading suspension may impact investor sentiment and liquidity in advance of these significant developments.
Trading SuspensionStock Repurchase Program Terminates
Bowman Consulting Group Ltd. has terminated its common stock repurchase program, which had been authorized for up to $35 million. The Board of Directors had previously increased the authorization from $25 million to $35 million on November 29, 2024. As of that date, approximately $16 million remained available for repurchase. The program was set to terminate on July 31, 2025, and allowed for the purchase of common stock depending on market conditions, potentially through open market purchases or trading plans compliant with Rule 10b5-1. The company was not obligated to repurchase any specific number or dollar amount of shares, and the program could be suspended at the company's discretion.
Operational